SynthesisJournal of translational medicine2025
Translation of task-evoked negative BOLD response into aging and Alzheimer's disease: a systematic review of the current literature.
Synthesis in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stress, stress systems, and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- A Multimodal Dataset to Investigate Task-Evoked Negative BOLD Response and Neurodegeneration.Scientific data · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAging, mild cognitive impairment (MCI), Alzheimer's disease (AD), and individuals at risk for AD are associated with impaired negative blood-oxygen-level-dependent (BOLD) response (NBR) in task-evoked functional magnetic resonance imaging (fMRI) studies. In addition, autosomal dominant AD patients have exhibited NBR alterations in the default mode network (DMN) regions nearly a decade before any accumulation of amyloid-β (Aβ) or tau and subsequent memory decline. Studies examining exclusively the NBR are rare in clinical settings, but some existing studies using task-evoked fMRI also report alterations in the NBR. However, in many studies, NBR is often disregarded, left lingering in the shadows, or, more generally, masked out as a bothersome noise.
methodsWe reviewed the Embase, Scopus, and PubMed databases, and forward and backward citation tracking for studies published up to 6/11/2024. Included articles detailed the use of task-evoked fMRI (tb-fMRI) to investigate aging, AD, mild cognitive impairment (MCI), and early tau or Aβ deposition, with all results reported on NBR.
findingsFrom 319 records identified for aging, 154 records for tau or Aβ, and 159 records for AD and MCI, 42, 14, and 9 papers were included, respectively. Forward and backward citation tracking added 44, 3, and 55 papers, respectively resulting in 167 studies with 11310 individuals. A significantly reduced magnitude of NBR in some regions of the DMN in healthy aging compared with young participants and individuals with elevated Aβ levels, MCI, and AD compared to healthy aging was found in 57, 12, 17, and 14 studies, respectively.
interpretationThis review highlights the DMN NBR's importance in the AD continuum and underscores its potential as an early diagnostic biomarker when pharmacological treatment options can still alter the disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.